Skin And Skin Structure Infections (SSSI) Caused By Bacteria – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Skin And Skin Structure Infections (SSSI) Caused By Bacteria – Drugs In Development, 2024 report and make more profitable business decisions.
Skin and Skin Structure Infections (SSSIs) caused by bacteria encompass a spectrum of infections affecting the skin and underlying tissues, varying from mild to severe and instigated by diverse bacteria. Notable culprits include Staphylococcus aureus, including methicillin-resistant strains (MRSA), Streptococcus pyogenes (group A Streptococcus), and other streptococcal species. SSSI can manifest as cellulitis, erysipelas, impetigo, folliculitis, furuncles, and abscesses, with distinct clinical presentations. Risk factors include compromised immune function, chronic conditions, skin injuries, and surgery. Diagnosis relies on clinical evaluation and occasionally laboratory tests. Antibiotics tailored to the causative bacteria are pivotal for treatment, especially in severe cases or suspected MRSA infections. Prevention involves wound care, hygiene, and managing underlying conditions to avert complications like deep tissue infections or sepsis.
The Skin And Skin Structure Infections (SSSI) Caused By Bacteria drugs in development market research report provide comprehensive information on the therapeutics under development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Skin And Skin Structure Infections (SSSI) Caused By Bacteria | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 23 molecules, with 23 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Skin And Skin Structure Infections (SSSI) Caused By Bacteria therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Skin And Skin Structure Infections (SSSI) Caused By Bacteria pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Skin And Skin Structure Infections (SSSI) Caused By Bacteria treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AbbVie IncBasilea Pharmaceutica Ltd
Beijing FuKangren Bio-pharm Tech Co Ltd
Bharat Biotech Ltd
Bioversys AG
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Debiopharm International SA
Helperby Therapeutics Group Ltd
Innovation Pharmaceuticals Inc
ioGenetics Inc
KBP Biosciences Co Ltd
La Jolla Pharmaceutical Company
Melinta Therapeutics LLC
Merck & Co Inc
MerLion Pharmaceuticals Pte Ltd
MicuRx Pharmaceuticals Inc
Paratek Pharmaceuticals Inc
R-Pharm
Spexis AG
TAXIS Pharmaceuticals Inc
Therapeutic Systems Research Laboratories Inc
Validus Cellular Therapeutics Inc
Zai Lab Ltd
Table of Contents
Table
Figures
Frequently asked questions